source
- FDA cites Baxter’s inadequate oversight after repeated GMP violations at multiple plantsThe U.S. Food and Drug Administration has issued a warning letter to Baxter International, saying the company's leadership has failed to provide adequate oversight of its drug manufacturing operati…
- Crossover fundraisings may hit $4.2 billion in 2026, with 2025 rounds still leading historic totalsCrossover rounds are viewed as a bridge to public markets, with Jim Healy of Sofinnova Investments saying a large raise signals a company has reached a level of maturity and broader institutional i…